Advertisement
U.S. markets close in 5 hours 54 minutes
  • S&P 500

    5,253.63
    +5.14 (+0.10%)
     
  • Dow 30

    39,764.89
    +4.81 (+0.01%)
     
  • Nasdaq

    16,408.65
    +9.13 (+0.06%)
     
  • Russell 2000

    2,121.53
    +7.18 (+0.34%)
     
  • Crude Oil

    82.36
    +1.01 (+1.24%)
     
  • Gold

    2,224.50
    +11.80 (+0.53%)
     
  • Silver

    24.65
    -0.10 (-0.41%)
     
  • EUR/USD

    1.0814
    -0.0015 (-0.14%)
     
  • 10-Yr Bond

    4.2100
    +0.0140 (+0.33%)
     
  • GBP/USD

    1.2644
    +0.0006 (+0.05%)
     
  • USD/JPY

    151.2500
    +0.0040 (+0.00%)
     
  • Bitcoin USD

    71,042.28
    +1,790.54 (+2.59%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,962.85
    +30.87 (+0.39%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Xenon Pharmaceuticals to Participate at the William Blair Biotech Focus Conference 2021

BURNABY, British Columbia, July 13, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced its participation in a virtual fireside chat at the William Blair Biotech Focus Conference 2021.

Date:

Thursday, July 15, 2021

Time:

10 am – 10:45 am Eastern Time

Participants:

Ian Mortimer, President and CEO | Dr. Simon Pimstone, Executive Chair of the Board

Additional details along with a link to the live webcast can be found on the “Investors” section of Xenon’s website at http://investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event for 30 days. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:
Maria McClean
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com


Advertisement